Arch Virol . Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection

[tetano]

Arch Virol


. 2021 May 2.
doi: 10.1007/s00705-021-05070-6. Online ahead of print.
Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection


Seyed Mohammad Ali Hashemi ^{1 2} , Marijn Thijssen ³ , Seyed Younes Hosseini ¹ , Alijan Tabarraei ⁴ , Mahmoud Reza Pourkarim ^{3 5} , Jamal Sarvari ^{6 7}



Affiliations

• PMID: 33934196
• DOI: 10.1007/s00705-021-05070-6

Abstract

The SARS-CoV-2 pandemic has become one of the most serious health concerns globally. Although multiple vaccines have recently been approved for the prevention of coronavirus disease 2019 (COVID-19), an effective treatment is still lacking. Our knowledge of the pathogenicity of this virus is still incomplete. Studies have revealed that viral factors such as the viral load, duration of exposure to the virus, and viral mutations are important variables in COVID-19 outcome. Furthermore, host factors, including age, health condition, co-morbidities, and genetic background, might also be involved in clinical manifestations and infection outcome. This review focuses on the importance of variations in the host genetic background and pathogenesis of SARS-CoV-2. We will discuss the significance of polymorphisms in the ACE-2, TMPRSS2, vitamin D receptor, vitamin D binding protein, CD147, glucose-regulated protein 78 kDa, dipeptidyl peptidase-4 (DPP4), neuropilin-1, heme oxygenase, apolipoprotein L1, vitamin K epoxide reductase complex 1 (VKORC1), and immune system genes for the clinical outcome of COVID-19.